User must not reproduce, distribute, modify, create derivative works of, publicly display, publicly perform, republish, download, store, or transmit any of the material on our Website, except as follows: If User prints, copies, modifies, downloads, or otherwise uses or provides any other person with access to any part of the Website in breach of this Agreement, Users right to use the Website will stop immediately and User must, at the Companys option, return or destroy any copies of the materials User has made
Instead: R73.03 Prediabetes R73.9 Hyperglycemia, unspecified (if diabetes is not diagnosed) This avoids overcoding and maintains accuracy for early-stage glucose abnormalities in children
Recent Articles The Return of 503B Compounding of GLP-1 Medications Over the last two years, the surging demand for GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has created both clinical October 23, 2025 FDA Issues Import Alert on GLP-1s Following Launch of Green List On September 19, 2025, the FDA issued Import Alert 66-80, which authorizes field staff to detain without physical examination shipments of GLP-1 active pharmaceutical ingredients October 1, 2025 Thea GLP-1 Crossroads: What Pharmacies Must Know About Compliance, Coverage, and the Future of Access The surge of GLP-1 medications, from semaglutide products such as Ozempic and Wegovy to new therapies in the pipeline, has created one of September 4, 2025 Recent Webinars Navigating GLP-1 Compounding Webinar Series Stay ahead of the curve with our webinar series navigating the evolving regulatory landscape for GLP-1 compounding
This is why labeling your vial with the concentration is so important
